
Quarterly ResultAug 11, 2026, 04:15 PM
SELLAS Q2 Net Loss $9.6M; GPS Trial Nears 80th Event
AI Summary
SELLAS Life Sciences Group, Inc. reported a net loss of $9.6 million, or $0.05 per share, for the second quarter ended June 30, 2026, compared to a net loss of $6.6 million, or $0.07 per share, for the same period in 2025. The company maintained a strong cash position with $138.3 million in cash and cash equivalents as of quarter-end. Operationally, SELLAS is nearing the 80th event in its Phase 3 REGAL trial for GPS and has enrolled 28 patients in the Phase 2 trial for SLS009 in AML, with topline data anticipated in Q4 2026.
Key Highlights
- Net loss for Q2 2026 was $9.6 million, compared to $6.6 million in Q2 2025.
- Basic and diluted loss per share for Q2 2026 was $0.05, compared to $0.07 in Q2 2025.
- Research and development expenses increased to $6.3 million in Q2 2026 from $3.9 million in Q2 2025.
- General and administrative expenses rose to $4.4 million in Q2 2026 from $3.0 million in Q2 2025.
- Cash and cash equivalents totaled $138.3 million as of June 30, 2026.
- Phase 3 REGAL trial of GPS is approaching the pre-specified 80th event for final analysis.
- 28 patients enrolled in Phase 2 trial of SLS009 in newly diagnosed AML, with topline data expected in Q4 2026.
Price Impact
More from SLS